1185241-83-1

1185241-83-1 structure

Name: DPPE fumarate
Chemical Name: 2-(4-Benzylphenoxy)-N,N-diethylethanamine (2E)-2-butenedioate (1:1)
CAS Number: 1185241-83-1
Molecular Formula: C₂₃H₂₉NO₅
Molecular Weight: 399.480
Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
Create Date: 2018-06-04 01:57:26
Modify Date: 2024-01-12 19:21:24
Tesmilifene fumarate (DPPE fumarate), an H1C receptor antagonist, potentiates a wide range of cytotoxics and even to offer some protection of normal cells[1][2].

Name	2-(4-Benzylphenoxy)-N,N-diethylethanamine (2E)-2-butenedioate (1:1)
Synonyms	2-(4-Benzylphenoxy)-N,N-diethylethanamine (2E)-but-2-enedioate (1:1) 2-(4-Benzylphenoxy)-N,N-diethylethanamine (2E)-2-butenedioate (1:1) Ethanamine, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]-, (2E)-2-butenedioate (1:1)

Description	Tesmilifene fumarate (DPPE fumarate), an H1C receptor antagonist, potentiates a wide range of cytotoxics and even to offer some protection of normal cells[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Inflammation/Immunology Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
In Vitro	Tesmilifene may modulate the effects of 12(S)HETE in cancer cells, and indirectly, influence the susceptibility of cellular DNA to chemotherapy[1].
In Vivo	Tesmilifene (DPPE, 20 mg/kg (s.c.) and 20 μg (icv in 5 μL)) potentiated seizures induced by both convulsants[2]. Animal Model: Male BKTO mice (25-45 g)[2]. Dosage: 20 mg/kg (s.c.) and 20 μg (icv in 5 μL). Administration: S.C. and icv. Result: Potentiated seizures induced by both convulsants.
References	[1]. Mark Vincent, et al. Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses. 2006;66(4):715-31. [2]. G Sturman, et al. Modulation of the intracellular and H3-histamine receptors and chemically-induced seizures in mice Agents Actions. 1994 Jun;41 Spec No:C68-9.